 WAKEFIELD, Mass., March 05, 2021 GLOBE NEWSWIRE -- Innovation Pharmaceuticals OTCQB:IPIX the Company, a clinical stage biopharmaceutical company, today reports that eight sites are now participating in the Companys international Phase 2 clinical trial assessing Brilacidin as a novel therapeutic in hospitalized patients with COVID-19. 